We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Teladoc Deserves Patience Now: Too Early to Buy, Too Risky to Sell
Read MoreHide Full Article
Key Takeaways
Teladoc is evolving into a comprehensive platform with AI tools and expanded care programs.
TDOC's international revenues grew 12% in 2025, outpacing domestic growth trends.
Teladoc cut expenses 22.2% in 2025, targeting up to $308M Adjusted EBITDA in 2026.
Teladoc Health, Inc. (TDOC - Free Report) is a pioneer and global leader in the telemedicine industry. It has a broad international presence, serving clients, supporting medical operations, and reaching members worldwide. It operates through two main segments — Integrated Care and BetterHelp. It serves markets across North America, South America, Europe, Asia-Pacific and the Middle East.
The stock has fallen 0.6% over the past month compared with the industry’s 1.1% decline. The Zacks Medical sector and the S&P 500 composite have decreased 3% and 3.2%, respectively, in the said time frame.
Image Source: Zacks Investment Research
Zack’s Rank and Valuation of TDOC
Teladoc Health currently carries a Zacks Rank #3 (Hold).
From a valuation standpoint, the stock appears to be trading at a discount. With a market capitalization of approximately $940.2 million, the stock has a forward Price-to-Sales ratio of 0.37X, which is below the industry average of 0.44X, indicating a lower valuation compared to its peers. The company currently holds a Value Score of A.
Image Source: Zacks Investment Research
Where Do Estimates for TDOC Stand?
The consensus estimate for 2026 earnings is pegged at 86 cents per share, suggesting anupward revision of 1 cent over the past 30 days. The consensus estimate for 2026 revenues is pegged at $2.5 billion. TDOC beat on earnings in each of the trailing four quarters, delivering an average surprise of 29.4%.
Teladoc Health, Inc. Price, Consensus and EPS Surprise
Teladoc Health has evolved from a basic telehealth provider into a more comprehensive healthcare platform. It has expanded services like Primary360 and introduced cardiometabolic and preventive care programs.
Offerings such as Prism and Wellbound allow the company to move beyond one-time consultations toward continuous care. This creates a stronger ecosystem where members are more likely to stay engaged. At the same time, acquisitions like Catapult Health and UpLift are helping build a leaner, more global platform that is approaching a key inflection point for profitability.
Innovation, especially in artificial intelligence, remains central to Teladoc’s strategy. Platforms like Prism and Clarity use AI to highlight recommended screenings and streamline workflows, improving both efficiency and care quality. These tools enable the company to resolve most member concerns in a single visit.
Teladoc is steadily moving beyond simple video consultations to become a more integrated, data-driven clinical partner. Its upcoming AI-based solutions for hospital staff safety also open up higher-margin and B2B revenue opportunities.
TDOC’s growth strategy is balanced between acquisitions and international expansion. While the U.S. market is becoming saturated, international revenues continue to grow at a solid pace, rising 12% in 2025 and outperforming domestic growth. The transition of BetterHelp toward an insurance-based model is expected to unlock additional revenue streams. Recent acquisitions further strengthen Teladoc’s capabilities and expand its global reach.
On the financial side, Teladoc is showing improved discipline. Total expenses declined 22.2% year over year in 2025, driven by workforce optimization and a reduced real estate footprint. This has helped protect margins and support Adjusted EBITDA, which is projected to reach up to $308 million in 2026. Overall, these efforts point to a clearer and more credible path toward profitability.
Key Risks to Consider
Despite its growth potential, there are a few concerns that investors should consider.
The BetterHelp segment, once a key growth driver for Teladoc Health, has become a concern. In 2025, segment revenues declined 9%. Although the company is shifting toward an insurance-reimbursed model to improve affordability, the transition is still in its early stages. If this move does not offset ongoing churn in the market, the segment could continue to weigh on overall valuation.
TDOC faces rising competition in the virtual care space from major players, which could put pressure on pricing. Profit remains volatile, with an accumulated deficit of $16.4 billion as of 2025, caused by heavy investments in customer acquisition, provider networks and technology development.
Conclusion
Given the mix of positives and risks, a wait-and-see approach appears prudent for Teladoc Health. Investors may want to closely track progress on profitability, stabilization in the BetterHelp segment, and overall growth trends before making a decisive move.
The Zacks Consensus Estimate for Phibro Animal Health's 2026 earnings is pegged at $3.03 per share, which moved up 1 cent over the past 30 days, indicating 45% year-over-year growth. The consensus estimate for 2026 revenues is pinned at $1.5 billion, indicating 14.5% year-over-year growth. PAHC beat earnings estimates in each of the trailing four quarters, delivering an average surprise of 20.2%.
The Zacks Consensus Estimate for Catalyst Pharmaceuticals’ 2026 earnings is pinned at $2.87 per share, which moved north 5 cents over the past 30 days. CPRX beat earnings estimates in each of the trailing four quarters, delivering an average surprise of 35.2%. The consensus estimate for 2026 revenues is pegged at $628.7 million, suggesting 6.7% year-over-year growth.
The Zacks Consensus Estimate for InnovAge's 2026 earnings is pegged at 25 cents per share, which has remained stable over the past 30 days, indicating 213.6% year-over-year growth. The consensus estimate for 2026 revenues is pinned at $944.5 million, indicating 10.6% year-over-year growth. INNV beat earnings estimates in three of the trailing four quarters and missed once, delivering an average surprise of 87.5%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
Why Teladoc Deserves Patience Now: Too Early to Buy, Too Risky to Sell
Key Takeaways
Teladoc Health, Inc. (TDOC - Free Report) is a pioneer and global leader in the telemedicine industry. It has a broad international presence, serving clients, supporting medical operations, and reaching members worldwide. It operates through two main segments — Integrated Care and BetterHelp. It serves markets across North America, South America, Europe, Asia-Pacific and the Middle East.
The stock has fallen 0.6% over the past month compared with the industry’s 1.1% decline. The Zacks Medical sector and the S&P 500 composite have decreased 3% and 3.2%, respectively, in the said time frame.
Image Source: Zacks Investment Research
Zack’s Rank and Valuation of TDOC
Teladoc Health currently carries a Zacks Rank #3 (Hold).
From a valuation standpoint, the stock appears to be trading at a discount. With a market capitalization of approximately $940.2 million, the stock has a forward Price-to-Sales ratio of 0.37X, which is below the industry average of 0.44X, indicating a lower valuation compared to its peers. The company currently holds a Value Score of A.
Image Source: Zacks Investment Research
Where Do Estimates for TDOC Stand?
The consensus estimate for 2026 earnings is pegged at 86 cents per share, suggesting anupward revision of 1 cent over the past 30 days. The consensus estimate for 2026 revenues is pegged at $2.5 billion. TDOC beat on earnings in each of the trailing four quarters, delivering an average surprise of 29.4%.
Teladoc Health, Inc. Price, Consensus and EPS Surprise
Teladoc Health, Inc. price-consensus-eps-surprise-chart | Teladoc Health, Inc. Quote
Business Tailwinds for TDOC
Teladoc Health has evolved from a basic telehealth provider into a more comprehensive healthcare platform. It has expanded services like Primary360 and introduced cardiometabolic and preventive care programs.
Offerings such as Prism and Wellbound allow the company to move beyond one-time consultations toward continuous care. This creates a stronger ecosystem where members are more likely to stay engaged. At the same time, acquisitions like Catapult Health and UpLift are helping build a leaner, more global platform that is approaching a key inflection point for profitability.
Innovation, especially in artificial intelligence, remains central to Teladoc’s strategy. Platforms like Prism and Clarity use AI to highlight recommended screenings and streamline workflows, improving both efficiency and care quality. These tools enable the company to resolve most member concerns in a single visit.
Teladoc is steadily moving beyond simple video consultations to become a more integrated, data-driven clinical partner. Its upcoming AI-based solutions for hospital staff safety also open up higher-margin and B2B revenue opportunities.
TDOC’s growth strategy is balanced between acquisitions and international expansion. While the U.S. market is becoming saturated, international revenues continue to grow at a solid pace, rising 12% in 2025 and outperforming domestic growth. The transition of BetterHelp toward an insurance-based model is expected to unlock additional revenue streams. Recent acquisitions further strengthen Teladoc’s capabilities and expand its global reach.
On the financial side, Teladoc is showing improved discipline. Total expenses declined 22.2% year over year in 2025, driven by workforce optimization and a reduced real estate footprint. This has helped protect margins and support Adjusted EBITDA, which is projected to reach up to $308 million in 2026. Overall, these efforts point to a clearer and more credible path toward profitability.
Key Risks to Consider
Despite its growth potential, there are a few concerns that investors should consider.
The BetterHelp segment, once a key growth driver for Teladoc Health, has become a concern. In 2025, segment revenues declined 9%. Although the company is shifting toward an insurance-reimbursed model to improve affordability, the transition is still in its early stages. If this move does not offset ongoing churn in the market, the segment could continue to weigh on overall valuation.
TDOC faces rising competition in the virtual care space from major players, which could put pressure on pricing. Profit remains volatile, with an accumulated deficit of $16.4 billion as of 2025, caused by heavy investments in customer acquisition, provider networks and technology development.
Conclusion
Given the mix of positives and risks, a wait-and-see approach appears prudent for Teladoc Health. Investors may want to closely track progress on profitability, stabilization in the BetterHelp segment, and overall growth trends before making a decisive move.
Key Picks
Some better-ranked stocks in the broader Medical sector are Phibro Animal Health Corporation (PAHC - Free Report) , Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) and InnovAge Holding Corp. (INNV - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Phibro Animal Health's 2026 earnings is pegged at $3.03 per share, which moved up 1 cent over the past 30 days, indicating 45% year-over-year growth. The consensus estimate for 2026 revenues is pinned at $1.5 billion, indicating 14.5% year-over-year growth. PAHC beat earnings estimates in each of the trailing four quarters, delivering an average surprise of 20.2%.
The Zacks Consensus Estimate for Catalyst Pharmaceuticals’ 2026 earnings is pinned at $2.87 per share, which moved north 5 cents over the past 30 days. CPRX beat earnings estimates in each of the trailing four quarters, delivering an average surprise of 35.2%. The consensus estimate for 2026 revenues is pegged at $628.7 million, suggesting 6.7% year-over-year growth.
The Zacks Consensus Estimate for InnovAge's 2026 earnings is pegged at 25 cents per share, which has remained stable over the past 30 days, indicating 213.6% year-over-year growth. The consensus estimate for 2026 revenues is pinned at $944.5 million, indicating 10.6% year-over-year growth. INNV beat earnings estimates in three of the trailing four quarters and missed once, delivering an average surprise of 87.5%.